15 September 2023 Lysarc
Publication of ALYCANTE study in Nature Medic...
LYSA-LYSARC announces the publication in Nature Medicine of the ALYCANTE s...
01 March 2022 Lysarc
ARCs/TECs day at the SFH congress
10 February 2022 Lysarc
Launch of the VERLEN study
VERLEN est une étude qui vise à évaluer l'efficacité d'une nouvelle com...
13 December 2021 Lysarc
The 3000th patient included in REALYSA –...
10 December 2021 Lysarc
ASH 2021: LYSA and LYSARC to present their si...
14 November 2021 Lysarc
The 2020 academic clinical research activity ...
03 November 2021 Lysarc
1000 patients included in the DESCAR-T regist...
19 October 2021 Lysarc
Cell Therapy Innovation 360°
27 May 2021 Lysarc
Launch of BiCAR: an unprecedented clinical s...
27 April 2021 Lysarc
2000th patient included in REALYSA – th...
On April 22, 2021, at the University Hospital Center of Lyon Sud, was recru...
24 February 2021 Lysarc
Press release – Daiichi Sankyo and LYSA...
01 January 2021 Lysarc
Happy New Year 2021
03 September 2020 Lysarc
1000th patient included in REALYSA
On Friday 28th of August 2020, in the University Hospital Center of Dijon, ...
26 June 2020 Lysarc
Prof. Franck Morschhauser becomes President o...
Present since the beginnings of LYSA, Prof. Franck Morschhauser joined the ...
17 March 2020 Lysarc
Coronavirus COVID-19 epidemic
Message to our LYSA members, partners and colleagues...
05 March 2019 Lysarc
6th workshop ELI
« Which future for follicular lymphoma? »
27 November 2018 Lysarc
Lymphoma Associated with Breast Implants: LYS...
Not to be missed this evening on France 2 TV, in the program Cash Investiga...
21 December 2017 Lysarc
French Cooperative Groups in Oncology
Focus on their Contribution to the Fight against Cancer
15 December 2017 Lysarc
Olivier Hermine nominated at the French Acad...
On 5 December 2017, the plenary assembly of the French Académie des Scienc...